Overexpressing CD38 in KDM6A-KO MM cells only partially rescued Dara-mediated ADCC (Supplementary Fig. 3c, d), even when we utilized an anti-SLAMF7 mAb, elotuzumab, KDM6A KO MM cells continued to exhibit resistance to ADCC (Supplementary Fig. 4a, b). Here, SLAMF7 is linked to Miyoshi myopathy.